CAS 1627929-55-8

PLX51107

CAS : 1627929-55-8

Formule : C₂₆H₂₂N₄O₃

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 438.4779

Ref: IN-DA01EO5F

PLX51107

CAS : 1627929-55-8

PLX51107

Degré de pureté : ≥98%

Masse moléculaire : 438.48g/mol

Ref: 54-BUP04702

PLX51107

CAS : 1627929-55-8

PLX51107 is a potent and selective BET inhibitor (Kds: 1.6, 2.1, 1.7, and 5 nM for BRD2-BD1, BRD3-BD1, BRD4-BD1, and BRDT-BD1).

Formule : C₂₆H₂₂N₄O₃

Degré de pureté : 99.75%

Couleur et forme : Solid

Masse moléculaire : 438.48

Ref: TM-TQ0253

4-[6-(3,5-Dimethyl-4-isoxazolyl)-1-[(1S)-1-(2-pyridinyl)ethyl]-1H-pyrrolo[3,2-b]pyridin-3-yl]benzoic

Produit contrôlé

CAS : 1627929-55-8

Applications 4-[6-(3,5-Dimethyl-4-isoxazolyl)-1-[(1S)-1-(2-pyridinyl)ethyl]-1H-pyrrolo[3,2-b]pyridin-3-yl]benzoic Acid, is a potent and selective BET inhibitor.
References Ozar H. G. et al.: Cancer Discov. 2018 Apr;8(4):458-477.;

Formule : C₂₆H₂₂N₄O₃

Couleur et forme : Neat

Masse moléculaire : 438.48

Ref: TR-D468190

PLX 51107

CAS : 1627929-55-8

PLX 51107 is an anticancer agent that has been shown to inhibit the growth of urothelial carcinoma cells in vitro and in vivo. It has also been shown to have genotoxic effects on prostate cancer cells. PLX 51107 induces apoptosis through the activation of caspases and pro-apoptotic protein expression, which may be due to its ability to bind to toll-like receptor 4 (TLR4) on tumor cells. This drug has a number of beneficial effects, such as inducing cycle arrest and inhibiting cell proliferation by blocking transcriptional regulation. It also inhibits angiogenesis, which leads to tumor growth inhibition. PLX 51107 is effective against a broad range of cancers, including urothelial carcinoma, breast cancer, colon cancer, and prostate cancer. PLX 51107 is not currently approved for use in humans because it can cause gastrointestinal toxicity in rats and mice at higher doses.

Formule : C₂₆H₂₂N₄O₃

Degré de pureté : Min. 95%

Masse moléculaire : 438.48 g/mol

Ref: 3D-CQC92955